Global X Genomics & Biotechnology UCITS ETF (LON:GNOM)
London · Delayed Price · Currency is GBP · Price in USD 7.03
-2.15 (-23.41%)
Jun 19, 2026, 4:28 PM GMT
20.07% (1Y)
| Assets | 24.14M |
| Expense Ratio | 0.60% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +20.07% |
| Volume | 1,112 |
| Open | 9.18 |
| Previous Close | 9.18 |
| Day's Range | 7.03 - 9.29 |
| 52-Week Low | 5.73 |
| 52-Week High | 9.29 |
| Beta | 1.02 |
| Holdings | 53 |
| Inception Date | Nov 2, 2021 |
About GNOM
The Global X Genomics & Biotechnology UCITS ETF (GNOM LN) strives to deliver investment performance that broadly aligns with the price and income generated by the Solactive Genomics v2 Index, prior to the deduction of its fees and expenses.
Asset Class Equity
Category Theme
Stock Exchange London Stock Exchange
Ticker Symbol GNOM
Provider Global X
Index Tracked Solactive Genomics v2 Index - Benchmark TR Net
Performance
GNOM had a total return of 20.07% in the past year, including dividends. Since the fund's inception, the average annual return has been -16.01%.
Top 10 Holdings
43.57% of assets| Name | Symbol | Weight |
|---|---|---|
| Guardant Health, Inc. | GH | 5.40% |
| Legend Biotech Corporation | LEGN | 4.84% |
| Twist Bioscience Corporation | TWST | 4.76% |
| Illumina, Inc. | ILMN | 4.56% |
| Moderna, Inc. | MRNA | 4.16% |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 4.11% |
| Natera, Inc. | NTRA | 4.06% |
| Vertex Pharmaceuticals Incorporated | VRTX | 3.96% |
| Veracyte, Inc. | VCYT | 3.91% |
| BioMarin Pharmaceutical Inc. | BMRN | 3.81% |